gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin mdco piii data agtc readout
highlight week septemb septemb medicin compani buy chardan top pick
announc posit top-line result pivot phase studi trial
subcutan subq rnai therapeut inclisiran met primari secondari endpoint show durabl
potent efficaci well excel safeti trial enrol patient atherosclerot
hefh patient given posit result announc previous pivot phase trial
emphas long-held thesi mdco believ compani acquir year ahead agtc
buy report result announc posit interim data dose escal arm posit
data expans arm phase i/ii trial gt x-link retin pigmentosa
xlrp agtc also disclos data indic biolog activ phase i/ii trial
compani achromatopsia achm compani
addit announc pipelin expans includ gt program addit ophthalmolog indic dri
orphan indic undisclos central nervou system indic gensight biolog
neutral report data phase rescu trial gene therapi gt
leber hereditari optic neuropathi lhon week week data statist
separ vision sham-treat eye week etdr letter etdr
letter sham gensight guid file approv europ buy announc collabor
harvard medic school hm part agreement provid mm grant establish
allianc rna therapi modul immun system artimi initi harvard
research use mrna nanoparticl deliveri technolog studi immunolog diseas
also enter multi-year research agreement provid mm fund project
led dr ulrich von andrian studi migrat immun cell blood tissu
look forward septemb octob septemb octob european societi medic
oncolog emso confer held barcelona agenda includ adaptimmun unrat
unrat kite gilead unrat compani transgen unrat octob world muscl societi
annual congress take place copenhagen program includ amicu therapeut neutral
audent buy dynacur privat unrat unrat
spark neutral octob allianc regen medicin arm host cell gene
meet carlsbad ca agenda includ present numer compani interest
octob nation hemophilia foundat bleed disord confer take place anaheim ca program
includ unrat sigilon therapeut privat uniqur buy chardan top pick
octob european huntington associ eha host annual confer bucharest
hungari program includ roch unrat uniqur unrat octob
et host confer call present result phase i/ii trial
gt limb-girdl muscular dystrophi type
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
octob cell gene meet host arm carlsbad ca
pleas refer import disclosur inform regul analyst certif found page report
buy pt detail model meira franchis septemb amusa
meiragtx updat detail proprietari patient-bas model drive estim includ newli
reiter thesi summar key driver high-convict buy rate
model aav-gad parkinson diseas thu increas price target
 collabor equiti stake unrat janssen derisk valid cash-infus meira
 ird program fit predict chardan gene therapi framework target monogen diseas
achm achm xlrp clear suitabl phenotyp use tropic vector right deliveri
 meira on-going clinic program provid potenti upcom valuat inflect point strong
preclin pipelin strong balanc sheet pursu larger gt opportun
 meira lever gene regul via switch technolog
 meira flexibl scalabl cgmp manufactur de-risk
 meira move faster peer
mdco buy de-risk piii shine endpt septemb amusa
medicin compani announc posit top-line result pivot phase
studi trial subq rnai therapeut inclisiran met endpoint durabl potent efficaci
well excel safeti increas pt incorpor premium
trial ascvd inclisiran demonstr efficaci toler safeti
least favor observ treatment-rel liver renal laboratori abnorm
trial hefh patient inclisiran demonstr durabl potent efficaci well-
toler excel safeti gener well-balanc treatment group furthermor
treatment-rel liver renal laboratori abnorm open chanc easi win inclisiran
potenti blockbust us market opportun given safeti question repatha trial
given posit result announc previous pivot phase trial includ import
signal cardiovascular benefit news mark success complet pivot phase studi
mdco inclisiran featur promin novemb aha scientif session
buy arbitr decis crispr ip disput septemb livshit
intellia announc arbitr panel assess compani disput carib bioscienc
privat certain ip affirm tech question exclus licens intellia
agreement compani panel issu interim award conclud certain structur
chemic guid rna modif technolog fell within scope intellia exclus licens
per carib releas includ carib hybrid rna-dna chrdna technolog
engin guid technolog howev intellia current use tech activ program panel
indic carib exclus perpetu world-wide leaseback right chemic modifi guid rna
carib would abl use develop therapeut allogen cell therapi oncolog
program right would subject reason licens fee paid intellia negoti
see limit impact intellia given tech question use compani activ program
genet medicin news septemb septemb
unrat announc appoint dr david thomson chief oper offic septemb
unrat announc departur compani ceo presid septemb
unrat announc impd clearanc pi trial ex vivo lenti gt pkd septemb
sight fp neutral report data piii trial gt lhon septemb
gensight biolog report week data phase rescu trial gt lhon
gensight emphas clinic meaning improv versu nadir etdr letter
etdr letter sham result line phase revers trial despit
differ baselin time cours diseas trial recoveri best-correct visual acuiti
bcva exce result publish natur histori studi unpreced gene therapi trial
natur histori studi referenc present unrat annual meet
north-american neuro-ophthalmolog societi nano march studi lhon patient
achiev spontan clinic relev recoveri crr nadir compar rescu patient use
page
definit crr rescu studi statist signific differ likelihood
eye achiev crr compar sham-treat eye vs
rescu data report april averag chang visual acuiti nadir
etdr letter etdr letter sham note time believ updat data still
show materi differ sham-treat eye case data
arct buy appoint dr edward holm andi sassin board director septemb
unrat announc clinic hold piii trial ex vivo retrovir gt rdeb septemb
unrat announc initi pi trial car-t tx prostat cancer septemb
passag privat appoint dr gari romano chip cale gener counsel septemb
duke publish crispr-ca system transcript regul septemb
adicet privat announc appoint dr francesco galimi svp septemb
carsgen tx privat receiv prime design car-t tx multipl myeloma septemb
trvx unrat announc open ouh site pi trial ov melanoma septemb
sln gb unrat receiv mm mileston unrat rnai tx septemb
neurogen privat announc appoint christin mikail presid septemb
announc investig roch unrat -spark neutral merger septemb
deep genom privat announc clinic candid aso tx wilson diseas septemb
citi publish baff-r-target car-t approach treat cell malign septemb
arbor biotechnolog privat announc new patent cover enzym septemb
arct buy announc mm regist direct offer common stock septemb
buy announc research collab harvard mrna-bas immunotherapi septemb
announc research collabor harvard medic school hm develop mrna-bas
immunotherapi provid mm grant establish allianc rna therapi modul
immun system artimi use mrna nanoparticl deliveri technolog perform
research immunolog diseas
project fund artimi aim advanc basic understand fundament immunolog process
gener new mechanist insight pathogenesi immunolog diseas discov novel approach
prevent diagnosi therapi human diseas
also enter multi-year research agreement harvard use mrna technolog studi
manipul migrat immun cell blood tissu term agreement
provid mm support project led dr ulrich von andrian edward mallinckrodt jr professor
immunopatholog director center immun imag hm
collabor announc illustr interest modul immun system therapeut
purpos area focu scienc day may note time
intrigu bet mrna-bas immun system therapeut anoth new therapeut modal
unrat announc submiss cta gt bmn pku septemb
ly fp unrat announc appoint carol deffez board director septemb
agtc buy report result provid updat gt clinic trial septemb
agtc report result announc interim data dose escal arm
data expans arm phase i/ii trial xlrp data phase i/ii trial
data safeti monitor committe dsmc recommend
continu dose escal well dose pediatr patient across trial
dose escal arm xlrp trial data present patient dose peripher
patient dose central expans arm xlrp trial data present addit
patient dose central patient dose peripher vision stabl month post-
treatment measur visual field visual acuiti patient dose central evalu
page
visual sensit respons rate seen month post-treat defin improv mean
sensit bleb least differ test date patient dose central stabil improv
bcva month post-treat oct outcom show stabl ellipsoid zone measur
achm trial month post-treat patient mid dose cohort patient high dose
cohort trial patient mid dose cohort trial show clinic meaning
improv light discomfort measur ocular photosensit analyz
compani addit announc expans preclin pipelin agtc ad new asset
ophthalmolog program dri orphan ophthalmolog indic preclin pipelin also
expand includ new program undisclos central nervou system indic
tx privat announc appoint brian riley svp technic oper septemb
navega tx privat receiv sbir phase grant nih develop gt pain septemb
alsen fp unrat announc complet mm financ round hear loss septemb
qure buy publish factor ix activ gt deliveri padua variant vs wt nhp septemb
unrat announc appoint dr william seller board director septemb
buy announc grant us australian patent hsv-base gt septemb
ucla publish -globin lentivir vector improv titer gene transfer septemb
tx privat file ipo septemb
cureduchenn invest chameleon bioscienc privat next-gen aav gt platform septemb
compani mention report
page
page
select catalyst genet medicin coverag
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
initi phase i/ii clinic trial huntington diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi patient dose brillianc phase i/ii trial
report result phase i/ii ignit dmd trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
present top-lin data phase i/iia clinic trial wet
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
initi phase i/ii trial parkinson diseas mutat
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
initi phase ib trial beta-thalassemia
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
rituximab report preliminari phase cohort data r/r nhl
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl neutral
figur select price movement week end sep vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet therapytickerratingccm ptupsideclosechang changemc mm dicerna gene editingtickerratingccm ptupsideclosechang changemc mm pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
ultragenyx genetx
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
